GlassScriptPhysician profile
Carmen Cawley
NPI 1801903885
$7,609.93
in general payments reported to CMS, 2019-2025
46 companies · $969 in 2025
The $969 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $564 · 2021: $1,528 · 2022: $1,510 · 2023: $743 · 2024: $1,240 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.15 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $945.17 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $859.99 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $827.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $511.79 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $456.27 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $411.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $377.79 | 2020-2025 | |
| Amarin Pharma, INC. | $326.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.40 | 2020-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $247.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $213.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.97 | 2020-2024 | Jardiance, Synjardy |
| Abbott Laboratories | $197.11 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $193.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $146.50 | 2019-2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $124.99 | 2019 | |
| Esperion Therapeutics, INC. | $117.10 | 2021-2025 | Nexletol |
| Cequr Corporation | $111.09 | 2022 | |
| Aimmune Therapeutics, INC. | $104.82 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $88.14 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $84.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.19 | 2022 | |
| Merck Sharp & Dohme LLC | $67.60 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Radius Health, INC. | $58.15 | 2019-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $54.81 | 2019-2020 | |
| Ibsa Pharma INC. | $51.51 | 2022-2023 | Tirosint, Licart |
| Exact Sciences Corporation | $42.05 | 2025 | The Cologuard Plus Collection Kit |
| Vivus LLC | $36.08 | 2024 | Pancreaze |
| Amneal Pharmaceuticals LLC | $34.39 | 2022-2025 | Unithroid |
| Alfasigma USA, INC. | $31.58 | 2020 | |
| Boston Scientific Corporation | $30.10 | 2019 | |
| Inspire Medical Systems, INC. | $27.05 | 2025 | Inspire |
| Allergan, INC. | $26.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.39 | 2024 | Ajovy |
| Almatica Pharma LLC | $25.68 | 2025 | Teriparatide, Loreev Xr |
| Harmony Biosciences LLC | $24.43 | 2025 | |
| Dexcom, INC. | $23.80 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $21.02 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $20.92 | 2025 | Gemtesa |
| Lundbeck LLC | $18.19 | 2024 | Vyepti |
| Xeris Pharmaceuticals, INC. | $17.52 | 2025 | Gvoke Hypopen |
| Shield Therapeutics INC | $17.01 | 2023 | Accrufer |
| Currax Pharmaceuticals LLC | $15.84 | 2023 | Nexletol, Nexlizet, Contrave |
| Axsome Therapeutics, INC. | $15.30 | 2025 | Symbravo |
| Sanofi Pasteur INC. | $14.61 | 2019 | |
| Endo Pharmaceuticals INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Cawley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.